Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017
November 29, 2017 09:30 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...
Immuron Successfully Completes NASH Phase II Clinical Study Milestone
November 09, 2017 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...
Assembly Biosciences to Present at the Jefferies London Healthcare Conference
November 08, 2017 07:00 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress
November 02, 2017 16:52 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products...
Assembly Biosciences Announces Pricing of $60 Million Offering of Common Stock
November 02, 2017 00:40 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) (“Assembly” or the “Company”), a clinical-stage biotechnology company advancing a new class of oral...
MicroBiome Therapeutics Completes Series B Financing and Prepares to Launch First Microbiome Modulator Product
November 01, 2017 07:00 ET
|
MicroBiome Therapeutics, LLC
NEW ORLEANS, La., Nov. 01, 2017 (GLOBE NEWSWIRE) -- MicroBiome Therapeutics, LLC (MBT), a leading company applying the science of the gastrointestinal (GI) microbiome to promote health and wellness,...
Evivo™ Gains Health Canada Approval, Providing First International Expansion Opportunity
October 30, 2017 08:00 ET
|
Evolve Biosystems
DAVIS, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Evolve BioSystems, Inc., a microbiome company developing novel solutions to resolve infant gut dysbiosis, is pleased to announce that...
Summit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. difficile Infection
September 11, 2017 07:00 ET
|
Summit Therapeutics PLC
CAMBRIDGE, Mass. and OXFORD, United Kingdom, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for...
Assembly Biosciences Announces September Conference Participation
August 31, 2017 07:00 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
Taconic Biosciences Expands Microbiome Portfolio
May 04, 2017 15:14 ET
|
Taconic Biosciences
HUDSON, N.Y., May 04, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, global leader in genetically engineered mouse models and associated services and the only commercial provider of germ-free mice,...